Loading…
PDS Biotechnology Corporation is projected to rise to $1.16 by 2027, a +5% move from its current price of $1.11. PDSB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.03 | $1.11 | $1.20 | +0.02% |
| May 30 | $0.9977 | $1.11 | $1.24 | +0.04% |
| May 31 | $0.9742 | $1.11 | $1.27 | +0.06% |
| Jun 1 | $0.9549 | $1.11 | $1.29 | +0.08% |
| Jun 2 | $0.9381 | $1.11 | $1.32 | +0.11% |
| Jun 3 | $0.9233 | $1.11 | $1.34 | +0.13% |
| Jun 4 | $0.9099 | $1.11 | $1.36 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9099 | $1.11 | $1.36 | +0.15% |
| Week 2 | $0.8387 | $1.11 | $1.48 | +0.30% |
| Week 3 | $0.7881 | $1.11 | $1.58 | +0.45% |
| Week 4 | $0.7481 | $1.12 | $1.67 | +0.59% |
| Week 5 | $0.7146 | $1.12 | $1.75 | +0.74% |
| Week 6 | $0.6857 | $1.12 | $1.83 | +0.89% |
| Week 7 | $0.6602 | $1.12 | $1.91 | +1.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies in the United States.
Its lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
It has license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corporation (PDSB) is a healthcare stock currently trading at $1.11 with a market capitalization of $61.96M. It ranks 4445 by market cap.
The stock shows a bullish technical backdrop, with sentiment labeled as BULLISH, RSI14 at 50, and moving averages at SMA50 $0.9851 and SMA200 $0.9413. Support is at $0.901 and resistance at $1.43. The stock’s 30-day price range runs from $0.6739 to $1.83, and annualized volatility stands at 100%.
These nearby technical levels and the current price context help frame a near-term trading framework while the longer-term forecast envisions substantial upside growth from the current level.
A major floor 51.6% below — a decisive break under it would weaken the trend.
The nearest floor, 18.8% below — buyers have tended to step in here.
The nearest ceiling, 28.8% above — a clean break opens room to run.
A major ceiling 51.0% above — clearing it would confirm fresh momentum.
Key PDSB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PDSB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.12 | Sell | $1.13 | Sell |
| MA 10 | $1.19 | Sell | $1.14 | Sell |
| MA 20 | $1.14 | Sell | $1.13 | Sell |
| MA 50 | $0.9851 | Buy | $1.03 | Buy |
| MA 100 | $0.8853 | Buy | $0.9647 | Buy |
| MA 200 | $0.9413 | Buy | $1.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.06 | Neutral |
| Stoch RSI (14) | 20.80 | Neutral |
| CCI (20) | -15.09 | Neutral |
| Williams %R (14) | -74.42 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -11.20 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 25.58 | Neutral |
| TRIX (15) | 0.77 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 39.87 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.12 | Sell |
| ADX (14) | 14.52 | Neutral |
| ATR (14) | 0.09 | Info |
Near-term sentiment is constructive but balanced. The current price of $1.11 sits above both the SMA50 ($0.9851) and the SMA200 ($0.9413), which can imply a mild upside bias.
Momentum is roughly neutral, with RSI14 at 50. The key near-term levels to watch are support at $0.901 and resistance at $1.43. The stock has traded within a 30-day range of $0.6739 to $1.83, indicating potential for movement within that band.
Overall, the setup suggests potential for upside if execution of near-term catalysts aligns with the bullish backdrop, while remaining sensitive to downside risk should the stock test the low end of the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.537 | $1.11 | $1.57 | 0% | Neutral | |
| $0.8374 | $1.16 | $1.75 | +5% | Neutral | |
| $1.03 | $1.53 | $2.44 | +37% | Bullish | |
| $1.14 | $1.77 | $2.96 | +59% | Bullish | |
| $1.39 | $2.27 | $3.95 | +104% | Bullish | |
| $1.48 | $2.52 | $4.55 | +127% | Bullish | |
| $1.14 | $2.01 | $3.74 | +81% | Bullish | |
| $1.19 | $2.19 | $4.18 | +97% | Bullish | |
| $1.24 | $2.37 | $4.65 | +114% | Bullish | |
| $1.32 | $2.64 | $5.28 | +137% | Bullish | |
| $1.54 | $3.42 | $7.53 | +208% | Bullish | |
| $4.24 | $9.43 | $21.69 | +750% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.537 | $1.11 | $1.31 | +0.00% |
| June 2026 | $0.9249 | $1.11 | $1.38 | -0.08% |
| July 2026 | $0.9278 | $1.13 | $1.44 | +2.03% |
| August 2026 | $0.8507 | $1.05 | $1.37 | -7.09% |
| September 2026 | $0.8167 | $1.02 | $1.35 | -2.93% |
| October 2026 | $0.8864 | $1.12 | $1.50 | +9.65% |
| November 2026 | $0.9177 | $1.17 | $1.58 | +4.48% |
| December 2026 | $0.8899 | $1.14 | $1.57 | -2.19% |
Click any year to see its month-by-month PDSB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PDSB is projected to trade between $0.537 and $1.57, averaging $1.11 — a potential gain of 0% from today's $1.11. Price action looks broadly range-bound.
PDS Biotechnology Corporation's 2027 outlook centres on $1.16, within a $0.8374 to $1.75 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PDSB could reach as high as $2.44, with a base case around $1.53 and support toward $1.03 — roughly +37% from $1.11. Momentum favours further upside here.
Expect PDSB to range from $1.14 to $2.96 through 2029. The $1.77 average target implies a +59% move from current prices. That is up +16% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PDSB price prediction for 2030 points to an average of $2.27 (low $1.39, high $3.95) — a potential gain of +104% on today's $1.11. Momentum favours further upside here.
In 2031, PDSB is projected to trade between $1.48 and $4.55, averaging $2.52 — a potential gain of +127% from today's $1.11. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
PDS Biotechnology Corporation's 2032 outlook centres on $2.01, within a $1.14 to $3.74 range. That is -20% versus the projected 2031 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2033, PDSB could reach as high as $4.18, with a base case around $2.19 and support toward $1.19 — roughly +97% from $1.11. Buyers look set to stay in control over this stretch.
Expect PDSB to range from $1.24 to $4.65 through 2034. The $2.37 average target implies a +114% move from current prices. That is up +9% on the projected 2033 average. Momentum favours further upside here.
The PDSB price prediction for 2035 points to an average of $2.64 (low $1.32, high $5.28) — a potential gain of +137% on today's $1.11. Buyers look set to stay in control over this stretch.
In 2040, PDSB is projected to trade between $1.54 and $7.53, averaging $3.42 — a potential gain of +208% from today's $1.11. That is up +30% on the projected 2035 average. Momentum favours further upside here.
PDS Biotechnology Corporation's 2050 outlook centres on $9.43, within a $4.24 to $21.69 range. That is up +176% on the projected 2040 average. That marks a +750% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PDSB today (≈ 900.900901 PDSB) could be worth
$8,495.38
+$7,495.38 (+750%) by 2050 · US Dollar
Based on the average projected PDSB price of $9.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PDSBwould be worth at today's price.
$1,000 invested in PDSB on May 27, 2025 (≈ 699.300725 PDSB) would be worth
$776.22
-$223.78 (-22.4%) today · 0.78× · US Dollar
Based on a PDSB entry price of $1.43 vs. today's $1.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.03 | $1,077.67 | +7.8% |
| 1 month ago | $0.93 | $1,193.55 | +19.4% |
| 3 months ago | $0.699 | $1,587.98 | +58.8% |
| 6 months ago | $0.771 | $1,439.69 | +44.0% |
| 1 year ago | $1.43 | $776.22 | -22.4% |
| All time (5.0y) ago | $10.86 | $102.21 | -89.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PDSB forecast.
Our base-case forecast reaches $2.20 around 2030.
Implied market cap at $2.20: $122.79M
The multi-year forecast points to a bullish trajectory with higher average prices and meaningful upside by 2030 and beyond. In 2026, the average price is projected at $1.11 (min $0.537, max $1.57) with ROI 0 and sentiment NEUTRAL.
By 2030, the average is $2.27 with a max of $3.95 and a min of $1.39, reflecting ROI 104.2 and a bullish tone. The forecast continues to trend higher through 2031 ($2.52 average), 2032 ($2.01), 2033 ($2.19), 2034 ($2.37), and 2035 ($2.64), with increasingly bullish sentiment in the latter years.
The outlook strengthens notably for 2040, where the average is $3.42 and the max is $7.53, delivering ROI 208.3 and a bullish sentiment. By 2050, the average rises to $9.43 and the max to $21.69, with ROI 749.5 and a bullish stance throughout the long horizon. These figures illustrate a path toward higher pricing while acknowledging that outcomes depend on clinical development progress and regulatory outcomes.
These are estimates, not guarantees. The forecast reflects the modeled projections and the inherent uncertainty of a clinical-stage biotechnology company, including variability in trial results and approvals that could alter the trajectory.
Tap a question to reveal the answer.
The forecast shows min $1.39, avg $2.27, max $3.95; ROI 104.2; sentiment BULLISH.
Forecasts suggest a bullish trajectory with 2030 avg $2.27 and 2050 avg $9.43, plus maxs like $21.69. ROI rises to 104.2% by 2030 and 749.5% by 2050, with sentiment turning BULLISH from 2028 onward. These are estimates and not guaranteed.
Yes. The forecast max for 2035 is $5.28 and the 2040 max is $7.53, indicating potential to surpass $5 under the projected path.
Current price is $1.11 and market cap is $61.96M. The stock ranks 4445 by market cap.
For 2040, the min is $1.54, the avg is $3.42, and the max is $7.53; ROI is 208.3 and the sentiment is BULLISH.
PDS Biotechnology Corporation Community Discussion
0Share your PDS Biotechnology Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.